Arriola, E, Gonzalez-Cao, M, Domine, M, De Castro, J, Cobo, M, Bernabe, R, Navarro, A, Sullivan, I, Trigo, JM, Mosquera, J, Crama, L, Isla, D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1)DOI:10.1007/s40487-021-00182-0. PMID:35032007. IF:(Q/D).

Remon, J, Bernabe, R, Diz, P, Felip, E, Gonzalez-Larriba, JL, Lazaro, M, Mielgo-Rubio, X, Sanchez, A, Sullivan, I, Massutti, B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02788-w. PMID:35122634. IF:3.400(Q3/6D).

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02816-9. PMID:35303269. IF:3.400(Q3/6D).

Palassini, E, Mir, O, Grignani, G, Vincenzi, B, Gelderblom, H, Sebio, A, Valverde, C, Baldi, GG, Brunello, A, Cardellino, GG, Marrari, A, Badalamenti, G, Martin-Broto, J, Ferraresi, V, Libertini, M, Turano, S, Gataa, I, Collini, P, Dei Tos, AP, Gennaro, M, Bini, F, Provenzano, S, Lo Vullo, S, Mariani, L, Le Cesne, A, Casali, PG. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. BREAST CANCER RESEARCH AND TREATMENT. 2022; 192(3)DOI:10.1007/s10549-022-06524-4. PMID:35150367. IF:3.800(Q2/5D).

Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8)DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3.300(Q3/6D).

Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3)DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12.600(Q1/1D).

Wu, YL, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, SW, Kato, T, Laktionov, K, Vu, HV, Wang, ZJ, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Atasoy, A, Herbst, RS, Tsuboi, M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3)DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20.400(Q1/1D).

Sooy, RA, Han, JY, Dafni, U, Cho, BC, Yeo, CM, Nadal, E, Carcereny, E, de Castro, J, Sala, MA, Bernabee, R, Coate, L, Pulla, MP, Campelo, RG, Cuffe, S, Hashemi, SMS, Fruh, M, Massuti, B, Garcia-Sanchez, J, Domine, M, Majem, M, Sanchez-Torres, JM, Britschgi, C, Pless, M, Dimopoulou, G, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, RA, Peters, S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. ANNALS OF ONCOLOGY. 2022; 33(2)DOI:10.1016/j.annonc.2021.11.010. PMID:34839016. IF:50.500(Q1/1D).